Objective
The use of Mycoplasma pneumoniae or its closest relative M. genitalium engineered for the controlled delivery of therapeutic peptides or proteins in situ, i.e. where they currently reside, could open new possibilities for the treatment of lung and genital tract diseases.
Taking advantage of the parasite nature of M. pneumoniae to lung tissue, we plan to use genetically engineered forms of this bacterium for the local, and eventually conditional delivery of therapeutic proteins in the context of distinct and many times highly invalidating respiratory disorders, as a proof-of-concept of a new technology platform.
Results of the work done at the CRG on the two projects above shall be validated in vitro and in vivo and, if successful, constitute the basis for a licensing agreement, or eventually a spin-off company created to bring the engineered bacteria or modifications thereof into the clinic. Interestingly, additional applications could be proposed at some point to diseases of the genital tract using engineered M. genitalium as a living vector.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencesbiological sciencesmicrobiologybacteriology
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
You need to log in or register to use this function
Call for proposal
ERC-2012-PoC
See other projects for this call
Funding Scheme
CSA-SA(POC) - Supporting action (Proof of Concept)Host institution
08003 Barcelona
Spain